InsiderTrades

Form 4 for CORT CORCEPT THERAPEUTICS INC

Accepted 2024-06-05 00:00:00 ET · period of report 2024-06-03 · accession 0000950170-24-069612 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
M 2024-06-05 2024-06-03 CORT Robb Gary Charles Chief Business Off A - Grant $15.65 +3,636 21.3K +21% +$56.9K
2024-06-05 2024-06-03 CORT Robb Gary Charles Chief Business Off F - Tax $30.17 -724 19.5K -4% -$21.8K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-06-03 A A 1,818 $0.00 23,115 D — — (F6) Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. (F3) Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2 Common Common Stock 2024-06-03 A A 1,818 $31.30 21,297 D — — (F4) The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 3, 2024. (F5) In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. (F3) Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
3 Common Common Stock 2024-06-03 F D 724 $30.17 19,479 D — — (F2) The closing price on May 31, 2024 was used to calculate the withholding obligation. (F3) Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.